| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis.
|
J Biol Chem
|
2003
|
2.18
|
|
2
|
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
|
Arthritis Rheum
|
2009
|
2.14
|
|
3
|
Type I interferon: potential therapeutic target for psoriasis?
|
PLoS One
|
2008
|
2.08
|
|
4
|
Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines.
|
J Biol Chem
|
2001
|
2.07
|
|
5
|
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
|
Ann Rheum Dis
|
2011
|
1.91
|
|
6
|
PAK4 mediates morphological changes through the regulation of GEF-H1.
|
J Cell Sci
|
2005
|
1.75
|
|
7
|
Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.
|
Arthritis Rheum
|
2007
|
1.72
|
|
8
|
Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus.
|
Arthritis Rheum
|
2012
|
1.54
|
|
9
|
The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion.
|
Mol Cell Biol
|
2003
|
1.52
|
|
10
|
The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation.
|
Exp Hematol
|
2002
|
1.48
|
|
11
|
The plasma cell signature in autoimmune disease.
|
Arthritis Rheumatol
|
2014
|
1.47
|
|
12
|
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
|
Ann Rheum Dis
|
2011
|
1.37
|
|
13
|
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
|
Cancer Res
|
2011
|
1.22
|
|
14
|
Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus.
|
Hum Genomics Proteomics
|
2009
|
1.22
|
|
15
|
Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy.
|
Ann Neurol
|
2010
|
1.16
|
|
16
|
The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn).
|
Oncogene
|
2002
|
1.11
|
|
17
|
Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.
|
Cancer Res
|
2012
|
1.11
|
|
18
|
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
|
J Pharmacol Exp Ther
|
2010
|
1.09
|
|
19
|
MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
|
Int J Oncol
|
2012
|
1.08
|
|
20
|
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.
|
Ann Rheum Dis
|
2013
|
1.06
|
|
21
|
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
|
Clin Cancer Res
|
2006
|
1.06
|
|
22
|
A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children.
|
Vaccine
|
2010
|
1.05
|
|
23
|
Retracted
Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target.
|
Mol Cancer Res
|
2010
|
1.05
|
|
24
|
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.
|
Blood
|
2008
|
1.04
|
|
25
|
The Ste20 kinase MST4 plays a role in prostate cancer progression.
|
Cancer Res
|
2003
|
1.03
|
|
26
|
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
|
Mol Cancer Ther
|
2009
|
0.98
|
|
27
|
Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies.
|
Arthritis Rheumatol
|
2014
|
0.97
|
|
28
|
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
|
Br J Haematol
|
2011
|
0.97
|
|
29
|
Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
|
J Immunother
|
2007
|
0.95
|
|
30
|
Altered expression of insulin receptor isoforms in breast cancer.
|
PLoS One
|
2011
|
0.95
|
|
31
|
Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
|
Arthritis Res Ther
|
2010
|
0.95
|
|
32
|
Type I interferons in Sjögren's syndrome.
|
Autoimmun Rev
|
2012
|
0.94
|
|
33
|
MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.
|
Pigment Cell Melanoma Res
|
2014
|
0.93
|
|
34
|
microRNA-mediated regulation of innate immune response in rheumatic diseases.
|
Arthritis Res Ther
|
2013
|
0.91
|
|
35
|
TRAF6-dependent Act1 phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-κB activation.
|
Mol Cell Biol
|
2012
|
0.90
|
|
36
|
Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles.
|
Muscle Nerve
|
2010
|
0.90
|
|
37
|
Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
|
Int J Rheum Dis
|
2011
|
0.90
|
|
38
|
Biomarkers for systemic lupus erythematosus.
|
Int J Rheum Dis
|
2012
|
0.88
|
|
39
|
Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases.
|
Bioorg Med Chem
|
2003
|
0.87
|
|
40
|
EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
|
Cancer Biol Ther
|
2012
|
0.85
|
|
41
|
Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production.
|
Clin Immunol
|
2010
|
0.83
|
|
42
|
Genomic signatures characterize leukocyte infiltration in myositis muscles.
|
BMC Med Genomics
|
2012
|
0.80
|